Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

BACKGROUND: Malignant cells of classical Hodgkin lymphoma (cHL) are characterised by genetic alterations at the 9p24·1 locus. This leads to overexpression of the programmed death 1 (PD-1) ligands and enables tumour cells to evade immune surveillance. A phase 1b study showed that nivolumab, a PD-1-bl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M, Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B, Collins, Graham, Savage, Kerry J, Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto, Parker, Susan M, Rodig, Scott, Roemer, Margaretha GM, Ligon, Azra H, Engert, Andreas
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5541855/
https://ncbi.nlm.nih.gov/pubmed/27451390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30167-X
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы